Disorder "Asthma"
Found 58 records
Disorder information
Disorder name:
Asthma 
Disoder ID:
Synonyms:
malignant tumor of abdomen (disorder),Exercise induced asthma,bronchial hyperreactivity,chronic obstructive asthma,chronic obstructive asthma with acute exacerbation,chronic obstructive asthma with status asthmaticus,exercise-induced asthma 
Definition:
A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has_symptom recurring periods of wheezing (a whistling sound while breathing), has_symptom chest tightness, has_symptom shortness of breath, has_symptom mucus production and has_symptom coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.? 
Modifier statisitcs
Record:
58 
Gene:
23 
Variant:
41 
Reference:
11 
Effect type:
Expressivity(57) ,Penetrance(1)  
Modifier effect:
Risk factor(19) ,Altered response to corticosteroid(7) ,Altered response to leukotriene modifiers(4) ,Altered response to montelukast(4) ,Altered response to zileuton and montelukast therapy(4) ,Altered response to therapy(3) ,Altered morning PEF(2) ,Altered response to asthma therapy(2) ,Altered response to b2AR agonist(2) ,Altered response to zileuton therapy(2) ,Promoting asthmatic phenotype(2) ,Altered bronchodilator response(1) ,Altered incidence(1) ,Altered plasma concentrations of montelukast(1) ,Altered response for lung function(1) ,Altered response to inhaled corticosteroid(1) ,Altered response to treatment(1) ,Altered severity(1)  
Modifier gene Variant Effect type Modifier effect Evidence Effect PubMed ID
FBXL7 FBXL7:rs10044254 Expressivity  Altered response to inhaled corticosteroid  P=9.16×10(-8)  rs10044254, associated with both decreased expression of FBXL7 and improved symptomatic response to ICSs in 2 independent pediatric cohorts.more more
DUSP1 DUSP1:c.-600C>T Expressivity  Altered bronchodilator response  From review article  Mutations in DUSP1 is Associated with bronchodilator response and asthma control in the presence of corticosteroidsmore more
CYSLTR2 CYSLTR2:c.*1493A>G Expressivity  Altered morning PEF  From review article  Mutations in CYSLT2 is Associated with morning PEF in subjects taking montelukastmore more
CYSLTR2:c.*1493A>G Expressivity  Altered response to montelukast  P=0.02  CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy.more more
CYSLTR2:rs91227 Expressivity  Altered morning PEF  From review article  Mutations in CYSLT2 is Associated with morning PEF in subjects taking montelukastmore more
CYSLTR2:rs91227 Expressivity  Altered response to montelukast  P=0.02  CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy.more more
CRHR1 CRHR1:c.-96-1309A>C Expressivity  Altered response to corticosteroid  From review article  Mutations in CRHR1 is Associated with corticosteroid responsemore more
CASP8 CASP8:c.1030G>C(p.Asp344His) Expressivity  Risk factor  P=0.033  rs1045485 in CASP8 was modestly associated with asthma in the Hispanic (P=0.033) populations,more more
CASP10 CASP10:c.922+243C>T Expressivity  Risk factor  P=0.0009  These data suggest a role for CASP10 as a potential modifier of the asthma phenotype, specifically with measures of airway obstruction and BHR.more more
CASP10:rs10166093 Expressivity  Risk factor  P=0.0033  These data suggest a role for CASP10 as a potential modifier of the asthma phenotype, specifically with measures of airway obstruction and BHR.more more
Total 58,Each Page
,Jump To
Page